PMC:7204657 / 253-429
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 23 | 60-68 | Species | denotes | patients | Tax:9606 |
| 27 | 9-20 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 33 | 51-59 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T4 | 51-59 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T4 | 74-75 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T4 | 9-20 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T5 | 0-176 | Sentence | denotes | Although tocilizumab may be beneficial in selected COVID-19 patients with a counterproductive hyperinflammatory phenotype, the efficacy and safety of such treatment is unknown. |